Wedmont Private Capital Has $806,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wedmont Private Capital grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 26.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,550 shares of the biopharmaceutical company’s stock after purchasing an additional 1,998 shares during the period. Wedmont Private Capital’s holdings in Gilead Sciences were worth $806,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Institute for Wealth Management LLC. lifted its position in Gilead Sciences by 1.9% during the 2nd quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 142 shares during the period. First Affirmative Financial Network lifted its position in Gilead Sciences by 3.5% during the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 147 shares during the period. Insigneo Advisory Services LLC increased its stake in shares of Gilead Sciences by 1.7% in the 2nd quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company’s stock valued at $661,000 after acquiring an additional 148 shares during the last quarter. MCF Advisors LLC increased its stake in shares of Gilead Sciences by 2.1% in the 1st quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after acquiring an additional 152 shares during the last quarter. Finally, Westside Investment Management Inc. increased its stake in shares of Gilead Sciences by 0.6% in the 2nd quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock valued at $1,826,000 after acquiring an additional 152 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler reissued an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a research note on Wednesday, September 11th. Robert W. Baird reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $78.00 to $100.00 in a research note on Monday. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

Gilead Sciences Stock Down 1.7 %

Shares of NASDAQ GILD opened at $84.67 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock has a market capitalization of $105.49 billion, a P/E ratio of 235.19, a PEG ratio of 2.91 and a beta of 0.18. The stock’s fifty day moving average is $79.54 and its 200 day moving average is $72.17.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.64%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.